The FDA and genetic testing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.Current opinion in lipidology · 2021
   Review
2. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.Journal of the National Comprehensive Cancer Network : JNCCN · 2017
   Article
3. Barriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panel.Applied & translational genomics · 2016
   Article

Corrections and comments

• Comment on
  The FDA and genomic tests--getting regulation right.2015

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as